Article
Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies.
Expert opinion on drug safety - 1 Nov 2012
Marcellin Patrick, Roberts Stuart K, Reddy K Rajender, Harrison Stephen A, Jensen Donald M, Hadziyannis Stephanos, Diago Moises, Weltman Martin, Messinger Diethelm, Tatsch Fernando, Rizzetto Mario
Abstract excerpt
OBJECTIVE: This analysis examines the safety profile of standard- versus high-dose peginterferon alfa-2a. METHODS: Data were pooled from five trials including HCV genotype 1- or 4-infected naive and treatment-experienced patients (n = 2,940). Patients were randomized to receive peginterferon alfa-2a at 180 μg/week (standard-dose; n = 1,672) or 360 μg/week (high-dose; n = 1,268) plus ribavirin 1,000/1,200 mg/day...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.